Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.
You may also be interested in...
AstraZeneca/Bristol's Onglyza Gains Approval, But Now Has To Face Januvia
Gaining FDA approval was only the first hurdle for AstraZeneca and Bristol-Myers Squibb's dipeptidyl peptidase-4 inhibitor Onglyza. A potentially even bigger challenge now lies ahead: positioning the drug against Merck's first-in-class blockbuster Januvia
AstraZeneca/Bristol's Onglyza Gains Approval, But Now Has To Face Januvia
Gaining FDA approval was only the first hurdle for AstraZeneca and Bristol-Myers Squibb's dipeptidyl peptidase-4 inhibitor Onglyza. A potentially even bigger challenge now lies ahead: positioning the drug against Merck's first-in-class blockbuster Januvia
AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared
AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.